RapImmune™ vs. Traditional Allergy Shots: The Real Numbers
We believe patients deserve transparent data to make informed decisions about their care. Here's what the published medical literature says about the true cost of allergy immunotherapy.
Two Paths to Allergy Relief. Very Different Economics.
Traditional allergy shots (subcutaneous immunotherapy, or SCIT) have been the gold standard for decades — and they work. But the 3–5 year commitment through commercial insurance carries costs that many patients don't see until they're deep into treatment. RapImmune™ delivers allergy immunotherapy through a fundamentally different approach.
Intralymphatic Immunotherapy
*Booster injection may be given if clinically indicated.
Allergy Shots (3–5 Year Course)
What Do Traditional Allergy Shots (SCIT) Actually Cost a Patient Over 5 Years?
Published claims data reveal costs that go far beyond the sticker price. Here's what a commercially insured patient can expect to pay out-of-pocket for a complete 5-year course of allergy shots — broken down by the numbers.
| Cost Category | PPO / HMO Plan | High-Deductible (HDHP) | Source |
|---|---|---|---|
| Per-visit copay / out-of-pocket (OOP) Average $32/visit across plan types |
$30–$50/visit | Full negotiated rate until deductible met | Tkacz 20212 |
| Build-up & transition visits (Year 1) ~41 visits per recommended AAAAI protocol: 1–2×/week for ~5 months, then every other week, then monthly by ~month 10. (Note: Blume et al. observed 27.3 build-up visits/year in practice, likely reflecting missed appointments.) |
$1,640–$2,050 | $2,000–$3,200+ | AAAAI protocol; Blume 20154 |
| Maintenance visits (Years 2–5) ~17 visits/year × 4 years = 68 visits |
$2,720–$3,400 | $2,176–$4,000+ | Blume 20154 |
| Initial consultation & testing ~20% had consultation costs >$1,000 |
$100–$500 | $300–$1,000+ | Mao 20195 |
| Annual deductible contribution Avg $1,787 individual; resets each January. Testing and procedures apply toward deductible before coinsurance begins. |
Copays apply regardless of deductible; testing/procedures subject to deductible first | $2,418/yr avg — all services at full negotiated rate until met | KFF 20248 |
| Hospital facility fees (if applicable) Applies at hospital-owned practices only |
+$0–$22/visit (patient share) | +$0–$108/visit (until deductible) | Sen 2022, Neprash 20156 |
| ESTIMATED 5-YEAR PATIENT OOP (Direct) | $4,400–$6,000 | $5,500–$8,500+ |
Why the range? Your actual cost depends on your plan type (PPO, HMO, HDHP), whether your allergist practices in a hospital-owned clinic vs. independent office, your specific deductible and coinsurance terms, and how many years you continue treatment. Published data consistently show that total payment for the same service in a hospital outpatient department is 145% higher than in a physician's office, with patient out-of-pocket costs 109% higher.6
Time Is a Cost. Here's How Much Traditional Allergy Shots (SCIT) Take.
Dollar figures tell only part of the story. Published research quantifies the enormous time burden of traditional allergy shots — time that compounds over years of treatment.
All three figures below refer to traditional allergy shots (SCIT) through insurance:
(travel + wait + injection + observation)4
(see methodology note below)9
(parking, tolls, other; national averages — may be lower in some markets)9
About the "4 hours" figure: A survey of 106 adult allergy shot patients and 191 caregivers found a median of 4 hours of work missed per injection visit.9 This reflects total work disruption, not literal time in the allergist's office. A mid-afternoon appointment means leaving work early, driving to the clinic, receiving the injection, completing the required 30-minute observation, and driving back — effectively losing the second half of a workday. Many employers don't allow partial-hour leave, so the practical impact is a half-day missed. Your actual time impact will depend on how close you live to your allergist's office, your work schedule flexibility, and your employer's leave policies.
+ ~17 visits/year × 4 years4
That's 118+ hours in the car, waiting room, and clinic — plus an estimated 436 hours of lost work productivity.9
at Allergenix over ~8 weeks.
All consultations, follow-ups, and oversight included in one transparent fee.
A booster injection may be given if clinically indicated.
Adding it up: At the published national average of $29/visit in travel costs over 109 visits, a traditional allergy shot patient spends approximately $3,161 in ancillary expenses alone — nearly matching the entire RapImmune™ program fee before you count a single copay. Ancillary costs may be lower in markets with free parking and no tolls.9
The Most Expensive Allergy Treatment Is the One You Don't Finish
Immunotherapy only works if patients complete the course. A minimum of 3 years is required for lasting benefit. The published completion rates tell a sobering story about traditional SCIT — and reveal one of RapImmune™'s most important advantages.
In a large study of 23,732 commercially insured patients, only 12.4% completed the recommended full course of allergy shots. Nearly one in four patients (23.9%) had their allergen serum mixed but never returned for a single injection — an average of $410 wasted per patient before treatment even began.2,3
The leading reason for premature discontinuation? Insufficient insurance coverage of allergen extracts and injection visits, cited by 40% of patients who dropped out. When health plans poorly reimburse the cost of allergy serum preparation and injection administration, practices may require higher patient copays, drop certain insurance plans, or require upfront payment — and patients bear the financial consequences. This was not about side effects (only 1.5% of discontinuations) or lack of effectiveness — it was about cost and coverage barriers making continued treatment unaffordable.10
Even in a military healthcare system where patients had zero out-of-pocket costs, only 34% completed 3+ years — demonstrating that the time and inconvenience burden alone drives significant attrition.7
In published intralymphatic immunotherapy (ILIT) clinical trials — the approach used in the RapImmune™ program — virtually every patient completes the 3-injection protocol. When treatment takes 3 visits instead of 100+, completion is no longer a barrier to lasting results.1
A note on data sources: The ILIT completion rates above come from clinical trials with enrolled, consented participants, while the allergy shot completion rates come from real-world insurance claims databases tracking tens of thousands of patients. These are not perfectly parallel comparisons. However, the fundamental point remains: a 3-visit protocol inherently eliminates the logistical, financial, and time barriers that drive the high attrition rates observed in multi-year allergy shot programs — regardless of the study setting.
The Total Economic Burden: Direct + Indirect Costs
When you combine the direct out-of-pocket expenses with the indirect costs of time, travel, and missed productivity, the full economic comparison becomes clear.
| Category | Traditional Allergy Shots (5 Years, PPO) | RapImmune™ |
|---|---|---|
| Direct medical OOP (copays, coinsurance, deductible) | $4,400–$6,0002,4,5 | $3,500 (all-inclusive) |
| Travel & ancillary costs ($29/visit, national avg.) Includes parking, tolls, other; may be lower in some markets |
$3,1619 | ~$87 (3 visits) |
| Lost work productivity (4 hrs/visit × $22/hr Iowa median wage) Published median work disruption per visit (Tankersley 2021); Iowa median hourly wage (BLS) |
$9,5929,11 | ~$264 |
| Facility fees (if hospital-owned practice) $0 at independent clinics; $22/visit patient share at hospital-owned |
$0–$2,3986 | $0 |
| Risk of wasted investment (non-completion) | 56–88% probability of incomplete course3,7 | ~0%1 |
| ESTIMATED TOTAL ECONOMIC BURDEN | $17,153–$21,151 | $3,851 |
Note on methodology: The traditional allergy shot ranges reflect conservative estimates from published peer-reviewed data. Visit count (~109 over 5 years) reflects the recommended clinical protocol: 1–2 injections per week during build-up (~5 months), tapering to every other week, then monthly maintenance for 3–4 years. Lower bounds assume a PPO plan at an independent (non-hospital) clinic. Upper bounds include HDHP cost-sharing, hospital facility fees, and higher regional costs.
On facility fees: The $0–$2,398 range reflects the fact that independent clinics charge no facility fee, while hospital-owned outpatient clinics charge a separate facility fee averaging $108/visit in the commercial market.6 At 20% coinsurance, that's ~$22/visit in additional patient OOP × 109 visits = $2,398. Not all allergists practice in hospital-owned settings — in the Des Moines area, for example, allergists currently practice in independent settings. But nationally, hospital-owned outpatient clinics are increasingly common, and patients should understand this cost differential.
On lost work productivity: The $9,592 figure uses the published median of 4 hours of work productivity lost per injection visit from Tankersley et al. (2021)9 multiplied by the Iowa median hourly wage of approximately $22/hr (U.S. Bureau of Labor Statistics).11 This represents total workday disruption — not literal time in the office. A mid-afternoon appointment may require leaving work 30–60 minutes early, plus 25 minutes of travel each way, check-in, injection, and 30-minute observation, effectively losing the second half of a workday. Your actual impact will vary with drive distance, work flexibility, appointment timing, and your individual wage.
On completion rates: The 56–88% incomplete-course range reflects the spread across multiple published studies: Tkacz et al. (2021) found only 12.4% completed the full recommended course in a large commercially insured U.S. population; Mendoza et al. (2023) found 34% completed 3+ years even with zero out-of-pocket costs in a military system; and Borg et al. (2020) found 57% completed 3 years in a Danish registry. Completion definitions vary across studies, but all confirm that a majority of patients who start allergy shots do not finish them.3,7
A Different Approach to Allergy Relief
RapImmune™ is a premium, physician-delivered intralymphatic immunotherapy (ILIT) program. Instead of repeated injections into the arm over years, small doses of allergen are placed directly into a lymph node under high-definition ultrasound guidance — targeting the immune system where tolerance is built.
The entire program consists of 3 ultrasound-guided injections over approximately 8 weeks, with all consultations, personalized lymphatic mapping, and follow-up care included in one transparent fee. A booster injection may be given if clinically indicated. Allergenix is currently the only practice in Iowa offering intralymphatic immunotherapy.
RapImmune™ is designed for patients with environmental allergies — pollen, dust mites, pets, and molds — who want rapid relief with evidence of sustained benefit in published clinical trials, without the 3–5 year commitment of traditional allergy shots.
A note on the evidence: ILIT is a newer immunotherapy approach that uses FDA-approved allergen extracts delivered via an off-label route (intralymphatic injection). The most comprehensive systematic review and meta-analysis to date pooled data from 15 randomized trials involving 582 patients, with cumulative enrollment across all published ILIT trials now estimated at approximately 800 participants.1 The evidence base is smaller and more recent than that supporting traditional allergy shots, which have been studied extensively for over a century. RapImmune™ uses only FDA-approved allergen extracts. Dr. Stanga discusses the clinical evidence, expected outcomes, and limitations of both approaches during every consultation so patients can make a fully informed decision.
All-inclusive. No hidden charges.
Over ~8 weeks
± booster if clinically indicated
in published ILIT trials1
Ready to Explore RapImmune™?
Schedule a consultation to discuss whether intralymphatic immunotherapy is right for your allergy profile. No referral needed. No insurance required.
Schedule a Consultation Or call us directly: 515-644-8448References
- Wang W, et al. Evaluation of safety, efficacy, and compliance of intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis of 15 RCTs (582 participants). Int Arch Allergy Immunol. 2023. / Liu L, et al. Is intralymphatic immunotherapy effective and safe for allergic rhinitis?: a meta-analysis of 11 RCTs (406 participants). Medicine. 2024. / Hoang MP, et al. Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis (483 participants). Rhinology. 2021. / Werner MT, Bosso JV. Intralymphatic immunotherapy for allergic rhinitis: a systematic review and meta-analysis of 17 trials. Allergy Asthma Proc. 2021. / Jiang S, et al. Evaluation of intralymphatic immunotherapy in allergic rhinitis patients: a systematic review and meta-analysis of 13 studies (454 participants). Mediators Inflamm. 2023.
- Tkacz J, et al. Real-world cost and utilization of allergy immunotherapy in a commercially insured U.S. population. Curr Med Res Opin. 2021;37(6).
- Tkacz J, et al. (2021) — Adherence data: 12.4% completed full course; 23.9% never returned for first injection; 41.2% discontinued during build-up. / Mao EJ, et al. (2019) — 15.1% inconsistent use in 131,493 SCIT patients.
- Year 1 visit count (~41) based on the AAAAI/ACAAI-recommended SCIT build-up protocol: 1–2 injections per week for approximately 5 months, tapering to every other week, then monthly by approximately month 10. Blume SW, et al. J Managed Care Spec Pharmacy. 2015;21(11) observed 27.3 visits/year during build-up in practice surveys, likely reflecting real-world adherence patterns including missed appointments. Maintenance visits (16.9/yr) from Blume. Direct medical cost $30.35/visit; 65.2 min total patient time per visit.
- Mao EJ, et al. Cost of SCIT in commercially insured patients: IBM MarketScan analysis of 131,493 patients. Curr Med Res Opin. 2019;35(8). / Bernstein DI, et al. Allergic rhinitis. JAMA. 2024. (~$5,000 for 5-year SCIT course.)
- Sen AP, et al. Site-of-service differential: total payment 145% higher, patient OOP 109% higher in hospital outpatient vs. physician office (102.7M commercial claims). Health Affairs. 2022. / Neprash HT, et al. Mean office visit price $108 higher in HOPD vs. office (MarketScan commercial). JAMA Intern Med. 2015.
- Mendoza KS, et al. SCIT adherence in military health system (no OOP costs): only 34% completed 3+ years. 2023.
- Kaiser Family Foundation. Employer Health Benefits Survey 2024. Average individual deductible $1,787; HDHP average $2,418.
- Tankersley MS, et al. Time use and indirect costs of subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol. 2021. Median 4 hours missed work/visit; $29/visit ancillary costs (parking, tolls, incidentals).
- Survey of 555 patients who discontinued SCIT: 40% cited insufficient insurance coverage of allergen extracts and injection visits as the leading reason — meaning their health plans poorly reimbursed these services, leaving patients with higher-than-expected out-of-pocket costs. Referenced in Gurgel RK, et al. AAO-HNS Clinical Practice Guideline on Immunotherapy. 2024.
- U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics (OEWS), May 2024. Iowa statewide median hourly wage approximately $22/hr (all occupations). Note: the Des Moines–West Des Moines MSA mean hourly wage is $31.09, making the $22/hr estimate conservative for the local market.
Data presented are derived from peer-reviewed publications and national survey data as cited. Cost estimates represent ranges based on published averages and may not reflect individual patient circumstances. SCIT out-of-pocket estimates incorporate copay, coinsurance, deductible, and facility fee data from multiple sources as noted. Indirect cost estimates use published median values. All Allergenix pricing is current as of 2026 and is available on our pricing page.